ALS untangled #83: clenbuterol

Area of Science:

• Pharmacology
• Neuroscience
• Muscle Physiology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Current treatments for ALS are limited, driving research into alternative therapies.
• Clenbuterol, a beta-2 adrenergic agonist, is being investigated for potential therapeutic effects in ALS.

Purpose of the Study:

• To review the potential of clenbuterol as a treatment for amyotrophic lateral sclerosis (ALS).
• To evaluate the biological effects of clenbuterol relevant to ALS pathophysiology.
• To assess the existing evidence and limitations of clenbuterol in ALS treatment.

Main Methods:

• Review of existing literature on clenbuterol's effects.
• Analysis of two mouse model studies for motor neuron disease.
• Examination of two open-label trials in people with ALS.

Main Results:

• Clenbuterol exhibits properties like muscle hypertrophy induction, mitochondrial function improvement, and neuroinflammation reduction, potentially beneficial for ALS.
• Preliminary studies in mouse models and human trials suggest possible benefits.
• Methodological flaws in current studies limit definitive conclusions.
• Significant and severe side effects were reported, leading to high dropout rates in trials and access programs.

Conclusions:

• Clenbuterol cannot be currently endorsed as an effective treatment for ALS due to insufficient evidence and safety concerns.
• Further rigorous studies are warranted to explore clenbuterol or similar beta-2 adrenergic agonists in ALS patients.
• The potential benefits must be weighed against the significant risk of adverse events.